Last Price$33.90.6%
Market Cap$15.2B
(3.8%)
Peers median - 18.9%
122.3%
Peers median - 2.8%
0.0%
Peers median - 5.2%
14.5%
Peers median - (13.8%)
Competing with RPRX
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$15.2B | 5.6 | $179.7 430.9% undervalued | 15.9% | $2,263.9M | $2,769.5M | (3.8%) | 122.3% | 73.9% | 14.5% | 0.0% | |
$402.0B | 6.7 | $60.0 32.9% overvalued | (29.6%) | DKK 290.4B | DKK 70.0B | 25.0% | 24.1% | 84.7% | 35.5% | 71.6% | |
$125.5B | 5.7 | $195.0 59.6% overvalued | 14.0% | $11.0B | ($790.3M) | 11.5% | (7.2%) | 86.1% | (15.0%) | 10.7% | |
$74.0B | 6.5 | $1,013.8 48.0% undervalued | (29.5%) | $14.2B | $3,597.2M | 8.3% | 25.3% | 86.7% | 25.0% | 5.7% | |
$38.1B | 5.8 | $109.1 82.5% overvalued | 59.5% | $2,258.9M | ($211.2M) | 127.3% | (9.4%) | 86.8% | (41.3%) | N/A | |
$31.3B | 5.2 | $93.6 61.6% overvalued | 62.3% | $2,248.2M | ($42.6M) | 23.0% | (1.9%) | 85.6% | (7.2%) | 1,931.9% | |
$27.1B | 6.3 | $165.8 48.6% undervalued | 24.9% | €3,040.1M | €985.3M | (54.1%) | 32.4% | 84.3% | (41.4%) | 1.3% | |
$14.8B | 5.6 | $46.7 33.6% overvalued | 17.6% | $4,241.2M | $235.2M | 14.8% | 5.5% | 92.3% | (12.7%) | 1.3% | |
$14.6B | 5.9 | $0.5 97.4% overvalued | 327.0% | $0.0 | ($142.1M) | N/A | N/A | N/A | (3,335.4%) | 1.9% | |
$14.0B | 7.7 | $427.2 37.8% undervalued | 35.5% | $2,877.4M | $1,080.6M | 23.6% | 37.6% | 89.2% | 65.4% | 4.7% | |
$1,846.9M | 5.4 | $2,805.1 1,137.3% undervalued | 39.9% | $3,316.8M | ($1,009.2M) | 50.5% | (30.4%) | 83.1% | (38.4%) | 32.1% |
Compare RPRX Valuation Multiples with Peers
LTM
NTM
1Y Forward
2Y Forward
EV/Revenue
General
Valuation Multiple
Financial metrics
Company name
EV/Revenue
Revenue growth
EBITDA margin
Net Income margin
Royalty Pharma plcRPRX
6.3x
(3.8%)
(43.7%)
37.9%
Median Peer Set
3.5x
18.9%
(47.6%)
0.4%
Alnylam Pharmaceuticals, Inc.ALNY
13.3x
23.0%
(38.6%)
(12.4%)
argenx SEARGX
N/A
198.6%
(60.5%)
(24.1%)
BeiGene, Ltd.BGNE
0.1x
73.7%
(56.5%)
(35.9%)
BioNTech SEBNTX
3.1x
(77.4%)
(89.7%)
24.4%
Incyte CorporationINCY
3.0x
14.8%
(94.0%)
0.8%
Novo Nordisk A/SNVO
10.2x
24.9%
142.8%
34.8%
Regeneron Pharmaceuticals, Inc.REGN
4.1x
8.3%
10.4%
31.1%
Summit Therapeutics Inc.SMMT
N/A
N/A
(68.7%)
N/A
United Therapeutics CorporationUTHR
3.8x
23.6%
25.7%
41.5%
Vertex Pharmaceuticals IncorporatedVRTX
11.0x
11.7%
N/A
(4.9%)
Compare RPRX Valuation Multiples Dynamics with Peers
Crunching data... Almost there!
FAQ
1. How does Royalty Pharma plc (RPRX) revenue growth compare to peers and the industry?
Royalty Pharma plc (RPRX) revenue growth is (3.8%), compared to the peers' median of 18.9%.
2. How does Royalty Pharma plc (RPRX) Free Cash Flow (FCF) margin compare to peers and the industry?
Royalty Pharma plc (RPRX) FCF margin is 122.3%, compared to the peers' median of 2.8%.
3. How does Royalty Pharma plc (RPRX) Total Debt to Equity ratio compare to peers and the industry?
Royalty Pharma plc (RPRX) Total Debt to Equity ratio is 0.0%, compared to the peers' median of 5.2%.
4. How does Royalty Pharma plc (RPRX) ROIC (Return on Invested Capital) compare to peers and the industry?
Royalty Pharma plc (RPRX) ROIC is 14.5%, compared to the peers' median of (13.8%).